Status:
UNKNOWN
CYP1A2, ABCB1, CYP2C9 and Plasma Concentration of Agomelatine in Adult Patients With Depression
Lead Sponsor:
Affiliated Hospital of Nantong University
Conditions:
Polymorphism, Genetic
Depression
Eligibility:
All Genders
18-69 years
Brief Summary
1. The plasma concentrations of agomelatine and its two metabolites are simultaneously determined by High performance liquid chromatography-tandem mass spectrometry; 2. The gene polymorphisms of CYP1A...
Detailed Description
1. research purpose and significance Through blood concentration monitoring, pharmacokinetics and gene detection technology, combined with clinical prospective research, the lean medication of agomela...
Eligibility Criteria
Inclusion
- Clinical diagnosis of depression; Sleep disorder.
Exclusion
- Mental disorder; Intelligence disorder; Dementia; Aphasia; Dysarthria; Consciousness disorder; Severe heart, kidney or liver dysfunction; Pregnant and lactating women; Malignant tumor.
Key Trial Info
Start Date :
October 31 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 31 2025
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06120543
Start Date
October 31 2023
End Date
March 31 2025
Last Update
November 7 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.